Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma
Source abstract
Abstract
Glioblastoma (GBM) is the most prevalent primary malignant brain tumor, characterized by a high mortality rate and a poor prognosis. The blood-brain barrier (BBB) and the blood-tumor barrier (BTB) present significant obstacles to the efficacy of tumor-targeted pharmacotherapy, thereby impeding the therapeutic potential of numerous candidate drugs. Targeting delivery of adequate doses of drug across the BBB to treat GBM has become a prominent research area in recent years. This emphasis has driven the exploration and evaluation of diverse technologies for GBM pharmacotherapy, with some already undergoing clinical trials. This review provides a thorough overview of recent advancements and challenges in targeted drug delivery for GBM treatment. It specifically emphasizes systemic drug administration strategies to assess their potential and limitations in GBM treatment. Furthermore, this review highlights promising future research directions in the development of intelligent drug delivery systems aimed at overcoming current challenges and enhancing therapeutic efficacy against GBM. These advancements not only support foundational research on targeted drug delivery systems for GBM but also offer methodological approaches for future clinical applications. The prospects for designing drug delivery systems include advancing these systems to clinical applications for the treatment of GBM. • The strategies and applications of non-invasive systemic drug delivery technologies for the treatment of glioblastoma (GBM) are illustrated comprehensively. • The application of cell membrane-coated nanoparticles, which offer a synergistic blend of advantages derived from both nanoparticles and biomimetic materials, is elaborately illustrated. • Extracellular vesicle-based drug delivery for GBM has been studied with a comparative analysis of sources from mammals, bacteria, and plants, highlighting the advantages of each. • Viral vectors, especially adeno-associated viruses, play a significant role in gene therapy for GBM, which is comprehensively discussed. • Highlighting the development objectives and future prospects of targeted drug delivery systems specifically designed for the treatment of GBM. • The challenges encountered by brain-targeted drug delivery systems during their translation to clinical application have been extensively analyzed, and appropriate strategies have been proposed to address them.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Management of glioblastoma: state of the art and future directions10.3322/caac.21613 ↗
2. Engineering nanomaterials for glioblastoma nanovaccination10.1038/s41578-024-00684-z ↗
3. INDIGO: a global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation10.1200/JCO.2023.41.17_suppl.LBA1 ↗
4. Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations10.1158/1078-0432.CCR-19-2182 ↗
5. Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery10.1039/D2BM01996E ↗
6. Brain-targeting drug delivery systems10.1002/wnan.1818 ↗
7. ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy10.1016/j.jconrel.2022.04.048 ↗
8. The blood-brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
9. Development and cell biology of the blood-brain barrier10.1146/annurev-cellbio-100617-062608 ↗
10. Blood-brain barrier: from physiology to disease and back10.1152/physrev.00050.2017 ↗
11. Strategies for delivering therapeutics across the blood-brain barrier10.1038/s41573-021-00139-y ↗
12. The blood-tumour barrier in cancer biology and therapy10.1038/s41571-021-00529-6 ↗
13. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
14. Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors10.3389/fonc.2020.00739 ↗
15. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies10.1016/j.apsb.2020.11.023 ↗
16. Danhong injection enhances the therapeutic effect of mannitol on hemispheric ischemic stroke by ameliorating blood-brain barrier disruption10.1016/j.biopha.2021.112048 ↗
17. Inhibiting autophagy flux and DNA repair of tumor cells to boost radiotherapy of orthotopic glioblastoma10.1016/j.biomaterials.2021.121287 ↗
18. Novel blood-brain barrier shuttle peptides discovered through the phage display method10.3390/molecules25040874 ↗
19. Engineered extracellular vesicle-delivered CRISPR/Cas9 for radiotherapy sensitization of glioblastoma10.1021/acsnano.2c12857 ↗
20. Fruit-derived extracellular-vesicle-engineered structural droplet drugs for enhanced glioblastoma chemotherapy10.1002/adma.202304187 ↗
21. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment
22. Emerging strategies to fabricate polymeric nanocarriers for enhanced drug delivery across blood-brain barrier: an overview10.1016/j.cis.2023.103008 ↗
23. Polymeric nanoparticles for drug delivery in glioblastoma: state of the art and future perspectives10.1016/j.jconrel.2022.07.023 ↗
24. Development and optimization of irinotecan-loaded PCL nanoparticles and their cytotoxicity against primary high-grade glioma cells10.3390/pharmaceutics13040541 ↗
25. Glycosylation of PAMAM dendrimers significantly improves tumor macrophage targeting and specificity in glioblastoma10.1016/j.jconrel.2021.07.018 ↗
26. Intranasal delivery of Borneol/R8dGR peptide modified PLGA nanoparticles co-loaded with curcumin and cisplatin alleviate hypoxia in pediatric brainstem glioma which improves the synergistic therapy10.1016/j.jconrel.2023.08.048 ↗
27. LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy10.1007/s12274-023-5568-3 ↗
28. Transformable "tubulin traps" interfere with mitochondrial autophagy and promote the elimination of glioblastoma
29. Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
30. ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy10.1002/adma.201903277 ↗
31. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy10.1126/sciadv.abm8011 ↗
32. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy10.1016/j.jconrel.2022.09.046 ↗
33. Smart nanomedicine to enable crossing blood-brain barrier delivery of checkpoint blockade antibody for immunotherapy of glioma10.1021/acsnano.1c08120 ↗
34. Hsp70-Targeting and size-tunable nanoparticles combine with PD-1 checkpoint blockade to treat glioma10.1002/smll.202300570 ↗
35. Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy10.1021/acsnano.1c07492 ↗
36. Nano-Codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma10.1021/acsnano.1c09794 ↗
37. P-selectin-targeted nanocarriers induce active crossing of the blood-brain barrier via caveolin-1-dependent transcytosis10.1038/s41563-023-01481-9 ↗
38. Engineering prodrug nanoparticles for targeted therapy in heterogeneous glioblastoma
39. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers10.1016/j.jconrel.2022.03.019 ↗
40. A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated10.1016/j.apsb.2020.07.024 ↗
41. A mitochondria-targeting lipid-small molecule hybrid nanoparticle for imaging and therapy in an orthotopic glioma model10.1016/j.apsb.2022.04.005 ↗
42. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery10.1136/jitc-2019-000207 ↗
43. Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy10.1016/j.jconrel.2020.12.036 ↗
44. Combined integrin αvβ3 and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect10.1186/s12951-021-01180-0 ↗
45. Doxorubicin-loaded liposome with the function of "killing two birds with one stone" against glioma10.1021/acsami.3c10364 ↗
46. Glucose and triphenylphosphonium Co-modified redox-sensitive liposomes to synergistically treat glioma with doxorubicin and lonidamine10.1021/acsami.1c02404 ↗
47. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy10.1126/sciadv.abc9450 ↗
48. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR-Cas gene editing10.1038/s41565-024-01769-0 ↗
49. RNA aggregates harness the danger response for potent cancer immunotherapy10.1016/j.cell.2024.04.003 ↗
50. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma10.1016/j.biomaterials.2022.121608 ↗
51. A virus-mimicking nucleic acid nanogel reprograms microglia and macrophages for glioblastoma therapy10.1002/adma.202006116 ↗
52. Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment10.1038/s41467-023-40280-3 ↗
53. Nanomedicine: a useful tool against glioma stem cells10.3390/cancers13010009 ↗
54. A state-of-the-art liposome technology for glioblastoma treatment10.1039/D3NR04241C ↗
55. Recent progress in bioconjugation strategies for liposome-mediated drug delivery10.3390/molecules25235672 ↗
56. Bright NIR-II emissive cyanine dye-loaded lipoprotein-mimicking nanoparticles for fluorescence imaging-guided and targeted NIR-II photothermal therapy of subcutaneous glioblastoma10.1186/s12951-024-03074-3 ↗
57. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis
58. Lipoprotein-biomimetic nanostructure enables tumor-targeted penetration delivery for enhanced photo-gene therapy towards glioma
59. Coating of a novel antimicrobial nanoparticle with a macrophage membrane for the selective entry into infected macrophages and killing of intracellular staphylococci
60. Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine10.1002/adma.201803717 ↗
61. Brain-targeted codelivery of bcl-2/bcl-xl and mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy10.1021/acsnano.2c00320 ↗
62. Biomimetic macrophage membrane-camouflaged nanoparticles induce ferroptosis by promoting mitochondrial damage in glioblastoma10.1021/acsnano.3c07555 ↗
63. Macrophage membrane-coated nanoparticles sensitize glioblastoma to radiation by suppressing proneural-mesenchymal transformation in glioma stem cells
64. Effective glioblastoma immune sonodynamic treatment mediated by macrophage cell membrane cloaked biomimetic nanomedicines10.1016/j.jconrel.2024.04.043 ↗
65. Multiple synergistic effects of the microglia membrane-bionic nanoplatform on mediate tumor microenvironment remodeling to amplify glioblastoma immunotherapy10.1021/acsnano.4c01253 ↗
66. Nanoparticles coated with brain microvascular endothelial cell membranes can target and cross the blood-brain barrier to deliver drugs to brain tumors
67. Genetically edited T-cell membrane coated AIEgen nanoparticles effectively prevents glioblastoma recurrence10.1016/j.biomaterials.2022.121981 ↗
68. Upconversion nanoparticle-based cell membrane-coated cRGD peptide bioorthogonally labeled nanoplatform for glioblastoma treatment10.1021/acsami.2c11284 ↗
69. A chlorotoxin-directed diselenide-bridged tumor-homing persistent luminescence nanoprobes mediating inhibition of oxidative phosphorylation for long-term near-infrared imaging and therapy of glioblastoma
70. A biomimetic nanomedicine targets orthotopic glioblastoma by combinatorial Co-delivery of temozolomide and a methylguanine-DNA methyltransferase inhibitor10.1002/adtp.202200095 ↗
71. Carrier-free highly drug-loaded biomimetic nanosuspensions encapsulated by cancer cell membrane based on homology and active targeting for the treatment of glioma
72. Biomimetic cell membrane-coated DNA nanoparticles for gene delivery to glioblastoma10.1016/j.jconrel.2021.08.021 ↗
73. Homotypic membrane-enhanced blood-brain barrier crossing and glioblastoma targeting for precise surgical resection and photothermal therapy10.1021/jacs.2c13701 ↗
74. Camouflaging nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood-brain barrier for imaging and therapy of brain tumors
75. Brain-targeting metastatic tumor cell membrane cloaked biomimetic nanomedicines mediate potent chemodynamic and RNAi combinational therapy of glioblastoma10.1002/adfm.202209239 ↗
76. Engineering and characterization of an artificial drug-carrying vesicles nanoplatform for enhanced specifically targeted therapy of glioblastoma
77. Reversing T cell dysfunction to boost glioblastoma immunotherapy by paroxetine-mediated GRK2 inhibition and blockade of multiple checkpoints through biomimetic nanoparticles
78. Biomimetic nanocomposites camouflaged with hybrid cell membranes for accurate therapy of early-stage glioma10.1002/anie.202304419 ↗
79. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy
80. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma10.1038/s41467-022-31799-y ↗
81. Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery10.1186/s12951-021-01110-0 ↗
82. Efficient delivery of lomitapide using hybrid membrane-coated tetrahedral DNA nanostructures for glioblastoma therapy10.1002/adma.202311760 ↗
83. Brain Co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy10.1002/adma.202203958 ↗
84. The biology, function, and biomedical applications of exosomes10.1126/science.aau6977 ↗
85. Brain endothelial cell-derived extracellular vesicles with a mitochondria-targeting photosensitizer effectively treat glioblastoma by hijacking the blood‒brain barrier10.1016/j.apsb.2023.03.023 ↗
86. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs10.7150/thno.39434 ↗
87. Glioblastoma-derived exosomes as nanopharmaceutics for improved glioma treatment
88. Targeting miR-9 in glioma stem cell-derived extracellular vesicles: a novel diagnostic and therapeutic biomarker10.1016/j.tranon.2022.101451 ↗
89. Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis10.1021/acsnano.9b04397 ↗
90. Mesenchymal glioma stem cells trigger vasectasia-distinct neovascularization process stimulated by extracellular vesicles carrying EGFR10.1038/s41467-024-46597-x ↗
91. Tumor-associated macrophage-derived exosomal LINC01232 induces the immune escape in glioma by decreasing surface MHC-I expression
92. EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP310.1186/s12943-021-01485-6 ↗
93. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas10.1093/neuonc/nox152 ↗
94. Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment10.7150/thno.60851 ↗
95. Tumor-derived exosomal microRNA-7-5p enhanced by verbascoside inhibits biological behaviors of glioblastoma in vitro and in vivo10.1016/j.omto.2020.12.006 ↗
96. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer10.1038/s41467-023-42365-5 ↗
97. Exosomes as drug delivery systems: a brief overview and progress update10.1016/j.ejpb.2020.07.026 ↗
98. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
99. Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy10.1186/s12935-022-02743-3 ↗
100. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy10.1002/advs.201801899 ↗